Making cures more common in kidney cancer

Published on October 31, 2023   41 min

Other Talks in the Series: Immunotherapy of Cancer

Please wait while the transcript is being prepared...
Hello, my name is David McDermott and I'm a Medical Oncologist here in Boston at Beth Israel Deaconess Medical Center. My talk today is entitled "Making Cures More Common in Kidney Cancer". Over the last 15 years, few areas in oncology have seen more progress than the treatment of advanced kidney cancer, due in large part to the effective application of immunotherapy. However, over the last year, you could make a strong argument that things haven't gone well for immunetherapy in kidney cancer. During my talk, I hope to convince you that to get our field back on track, advocates for immunotherapy will need to refocus on the field's roots, which were the rational application of immunotherapies to patients most likely to benefit. We'll also need to develop therapies that generate more remissions and ultimately cures.
Here are my disclosures.
I've divided my talk into three parts. In the second section, I will talk about how my colleagues are developing new tools to measure an important goal of our patients, remission of their kidney cancer. In the third section, I'll talk about how our team at the Dana Farber Harvard Cancer Center is exploiting a growing understanding of the kidney cancer tumor micro environment to develop therapies that might make remissions more common. I first started treating patients over 25 years ago when the median survival for our patients with metastatic kidney cancer was less than one year. Thanks to team efforts of patient advocacy groups, partners in industry, researchers in basic translational clinical science, and most importantly, our brave patients and their families; median survival is now close to five years, with patients presenting with metastatic disease. This improvement is due, in large part, to the durable benefit seen with immunotherapy. Let's start with a brief history of its application in solid tumors.